Skip to content

Comparison of different volumes of ropivacaine used for ultrasound-guided pericapsular nerve group (PENG) block in total hip arthroplasty

Comparison of different volumes of ropivacaine used for ultrasound-guided pericapsular nerve group (PENG) block in total hip arthroplasty

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069959
Enrollment
Unknown
Registered
2023-03-30
Start date
2023-03-30
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis of the hip, osteonecrosis of the femoral head (Ficat IIIB or IV), and developmental dysplasia of the hip.

Interventions

Control group:pericapsular nerve group block

Sponsors

Department of Anesthesiology, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who need unilateral primary THA surgery due to osteoarthritis of the hip joint, joint destruction, aseptic necrosis of the femoral head, femoral neck fracture, etc; (2) The age is 18-80 years old, regardless of gender; (3) Body mass index: 20-35 kg/m2; (4) The preoperative American Society of Anesthesiologists (ASA) anesthesia risk assessment was graded as Grade I-III; (5) Patients who have signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Long-term use of opioids (daily or almost daily use of opioids>3 months); (2) Alcohol or drug abuse or allergy to any drugs (local anesthetics, etc.) used in this study; (3) Psychopaths, language disorders, and inability to complete the visual analog scale (VAS); (4) Patients with neuropathy of the extremities on the surgical side have moderate or more joint deformities or stiffness on the surgical side; (5) Previous history of hip trauma, or bilateral hip sensory asymmetry; (6) Local skin infection and bleeding at the anesthesia puncture site; (7) Abnormal coagulation function (PT, APTT exceeding normal values, INR<=1.4), platelet count<80 × 109/L), patients with possible abnormal platelet function; (8) The surgeon or anesthesiologist believes that the patient is not suitable for inclusion; (9) Patients with surgery time greater than 90 minutes.

Design outcomes

Primary

MeasureTime frame
Dosage of morphine within 24 h after surgery;

Secondary

MeasureTime frame
Total morphine consumption during hospitalization;Intraoperative consumption of opioids;Postoperative Visual Analogue Scale Score at rest;Postoperative Visual Analogue Scale Score at motion;Postoperative quadriceps strength;Time until the first walkout of bed after surgery;postoperative adverse events;Time to hospital discharge;

Countries

China

Contacts

Public ContactYang Jing

West China Hospital, Sichuan University

yangjing@wchscu.cn+86 189 8060 2269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026